Computerized Cognitive Training for MCI
A Randomized Control Trial on Computerized Cognitive Training for Individuals With Mild Cognitive Impairment
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Introduction:
Mild cognitive impairment (MCI) is a clinical condition characterized of a reduction in memory and/or other cognitive processes that are insufficiently severe to be diagnosed as dementia, but are more pronounced than the cognitive decline associated with normal aging. The prevalence of MCI ranges from 3% to 19% in adults older than 65 years; some of these individuals seem to remain stable or return to normal over time, but more than half progress to dementia within 5 years. Thus, MCI represents a critical window of opportunity for intervening and altering the trajectory of both cognitive decline and loss of functional independence in older adults. Cognitive function apart from memory such as executive function is also impaired in patients with MCI. However, no study has yet placed sufficient emphasis on the training of executive function.
Objectives:
The objective of the study is to evaluate whether memory training combined with executive training could lead to improved cognitive and noncognitive performance in patients with MCI. Furthermore, we will explore the neural correlates underlying the changed performances.
Patients and Methods:
The proposed study is a single blinded, randomized and controlled trial that will include 120 elderly patients with MCI from the memory clinic. The groups will be randomized to either intervention or waiting-list group. The intervention is computerized combined memory and executive function training performed for 60 minutes x 4 times/week over 26 weeks. A neuropsychological assessment will be administered at baseline and week 4, 12 and 26 after the intervention. The structural and functional MRI, EEG and NIRS will be performed at baseline and week 26 after intervention for a sub-study on the effect of cognitive training on brain structure and function.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Huali Wang, MD
- Número de teléfono: +86-10-82801983
- Correo electrónico: huali_wang@bjmu.edu.cn
Copia de seguridad de contactos de estudio
- Nombre: Haifeng Zhang, MS
Ubicaciones de estudio
-
-
Beijing
-
Beijing, Beijing, Porcelana, 100191
- Reclutamiento
- Peking University Institute of Mental Health(Six Hospital)
-
Contacto:
- Haifeng Zhang, MS
- Número de teléfono: 86+18813185360
- Correo electrónico: zhfphd@gmail.com
-
Contacto:
- Xiaozhen Lv, PhD
- Número de teléfono: 86+82801983
- Correo electrónico: lxz120300@163.com
-
Investigador principal:
- Huali Wang, MD
-
Sub-Investigador:
- Haifeng Zhang, MS
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- An objective cognition impairment (a Montreal Cognitive Assessment (MoCA) score < 26)
- Preserved general cognitive function( an mini-mental state examination (MMSE) score of > 24)
- Clinical Dementia Rating (CDR) = 0.5
- Hamilton Depression Scale (HAMD) score of < 12
- Intact activities of daily living (ADL score of <=26)
- Schooling education > = 5 years)
- Not meeting the diagnosis of dementia (according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) and the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) Probable Alzheimer's Criteria
Exclusion Criteria:
- Serious visual or hearing impairment;
- Hachinski Ischemia Scale (HIS) >= 4;
- Subjects with Axis I disorders listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), any other neurological disorders that could affect cognitive function;
- currently on titration of medications with cognitive enhancers or antidepressants;
- having any physical condition that could preclude regular attendance and full intervention-program participation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Combined cognitive training
The training is combined executive function and memory training.
The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
|
Computerized combined executive function and memory training
|
|
Sin intervención: Waiting-list group
Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period.
During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Composite working memory z score
Periodo de tiempo: Change from baseline composite working memory z score at week 26
|
composite score of digit span and spatial span
|
Change from baseline composite working memory z score at week 26
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
cognitive test package (CTP)
Periodo de tiempo: Changes from baseline composite CTP score at week 26
|
composite score of episodic memory, speed processing, executive function, attention, language and social cognition
|
Changes from baseline composite CTP score at week 26
|
|
Self evaluated memory ability
Periodo de tiempo: Change from baseline self evaluated memory ability at week 26
|
Score on the questionnaire probes worries about memory (MMQ-contentment).
|
Change from baseline self evaluated memory ability at week 26
|
|
Brain Functional Imaging
Periodo de tiempo: change from baseline functional connectivity at week 26
|
Brain function measured with MRI.
|
change from baseline functional connectivity at week 26
|
|
Electrical activity of the brain
Periodo de tiempo: change from baseline electrical brain activity at week 26
|
Brain activity measured with electroencephalography (EEG).
|
change from baseline electrical brain activity at week 26
|
|
Brain structural imaging
Periodo de tiempo: change from baseline cortical thickness at week 26
|
cortical thickness measured with MRI
|
change from baseline cortical thickness at week 26
|
|
cerebral blood flow
Periodo de tiempo: change from baseline cerebral blood flow at week 26
|
Cerebral blood flow measured with Near-infrared spectroscopy (NIRS).
|
change from baseline cerebral blood flow at week 26
|
|
Mood
Periodo de tiempo: Change from baseline composite mood score at week 26
|
composite score of mood status
|
Change from baseline composite mood score at week 26
|
|
BDNF level
Periodo de tiempo: change from baseline serum BDNF level at week 26
|
Serum Brain-derived neurotrophic factor (BDNF) level
|
change from baseline serum BDNF level at week 26
|
|
Composite of overall cognition z scores
Periodo de tiempo: Changes from baseline composite overall cognition z score at week 26
|
Score on Montreal Cognitive Assessment (MoCA) and Mini-mental State Examination (MMSE).
|
Changes from baseline composite overall cognition z score at week 26
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Huali Wang, MD, Peking University Institute of Mental Health(Sixth hospital)
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Z161100000516001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .